A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

• Main Authors: Kai Chu (Author), Yuemei Hu (Author), Hongxing Pan (Author), Jingliang Wu (Author), Dandan Zhu (Author), Mariano M. Young (Author), Li Luo (Author), Zhuobiao Yi (Author), Peter C. Giardina (Author), William C. Gruber (Author), Daniel A. Scott (Author), Wendy Watson (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Streptococcus pneumoniae causes a considerable disease burden among children in China. Many isolates exhibit antimicrobial resistance but are often serotypes covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Because the approved infant immunization schedule in China allows PCV13 vacci...